Business
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France, May 28, 2026--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/3703465180ec83727a78cc4234b393e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G6WxTuofnlzVOiCnKpLSjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MA--/https://media.zenfs.com/en/business-wire.com/3703465180ec83727a78cc4234b393e8","width":960,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EdTMF2sGBxIzd.0kAnP9HA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNw--/https://media.zenfs.com/en/business-wire.com/3703465180ec83727a78cc4234b393e8","width":640,"height":107},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KroebY_5dMN604_6x3yC_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/3703465180ec83727a78cc4234b393e8","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, May 28, 2026--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.","length":454,"tagName":"p"},{"type":"text","content":"The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.","length":145,"tagName":"p"},{"type":"text","content":"Videoconference in English, 6:00pm CEST / 12:00pm ET>https://www.medincell.com/annual-results-2025-2026-register/","length":117,"tagName":"p"},{"type":"text","content":"During the videoconference, Medincell’s management team will provide an overview of the company’s performance and strategic outlook, followed by a Q&A session in English.","length":174,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescr...